173 related articles for article (PubMed ID: 18341668)
1. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.
Nath CE; Earl JW; Pati N; Stephen K; Shaw PJ
Br J Clin Pharmacol; 2008 Jul; 66(1):50-9. PubMed ID: 18341668
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
[TBL] [Abstract][Full Text] [Related]
3. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
[TBL] [Abstract][Full Text] [Related]
4. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
[TBL] [Abstract][Full Text] [Related]
5. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
[TBL] [Abstract][Full Text] [Related]
6. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.
Oechtering D; Schiltmeyer B; Hempel G; Schwab M; Würthwein G; Mürdter T; Klingebiel T; Vormoor J; Gruhn B; Fleischack G; Boos J
Anticancer Drugs; 2005 Mar; 16(3):337-44. PubMed ID: 15711187
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
10. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
13. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Bostrom B; Enockson K; Johnson A; Bruns A; Blazar B
Pediatr Transplant; 2003; 7 Suppl 3():12-8. PubMed ID: 12603688
[TBL] [Abstract][Full Text] [Related]
15. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
17. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of liposomal busulphan in man.
Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
[TBL] [Abstract][Full Text] [Related]
19. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
20. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
